Alemtuzumab (Campath-1H) in kidney transplantation

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Kidney transplantation has become the treatment of choice for both the quality of life and survival in patients with end-stage renal disease (ESRD). However, the immunosuppressive regimen which allows optimal kidney transplant outcome remains elusive. One of the more promising induction agents, Alemtuzumab, was introduced to kidney transplantation by Calne in the late 1990s with low dose cyclosporine A monotherapy, with the hope of establishing 'prope' or near tolerance. Subsequent pilot studies with Alemtuzumab alone or monotherapy (DSG, Rapa) demonstrated high rates of acute rejection (AR) along with occasional humoral components that lead to abandoning the concept of Alemtuzumab as a 'magic bullet' to achieve tolerance, prope or otherwise. A number of programs (including our own) has since modified maintenance immunosuppression using low dose tacrolimus, and shown acceptable rates of AR, with relatively low incidence of viral infection and lymphoproliferative disorders along with cost benefit. However, there are only three prospective, randomized studies which are small with one year or less follow-up, and most published series utilize historical control groups with relatively short follow-up. As extrapolation from short-term data is far from secure, long-term, prospective, randomized studies with Alemtuzumab will be necessary to determine the optimal immunosuppressive regimen.

Original languageEnglish
Pages (from-to)15-20
Number of pages6
JournalAmerican Journal of Transplantation
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Kidney Transplantation
Immunosuppressive Agents
Prospective Studies
Magic
Lymphoproliferative Disorders
Tacrolimus
Virus Diseases
Immunosuppression
Cyclosporine
Chronic Kidney Failure
Cost-Benefit Analysis
Maintenance
Quality of Life
Transplants
Kidney
Control Groups
Survival
alemtuzumab
Incidence
Therapeutics

Keywords

  • Acute rejection
  • Alemtuzumab
  • Induction therapy
  • Mycophenolate mofetil
  • Renal allograft
  • Sirolimus
  • Tacrolimus

ASJC Scopus subject areas

  • Immunology

Cite this

Alemtuzumab (Campath-1H) in kidney transplantation. / Ciancio, Gaetano; Burke, George W.

In: American Journal of Transplantation, Vol. 8, No. 1, 01.01.2008, p. 15-20.

Research output: Contribution to journalArticle

@article{0424f6e45ee34bb3b74b2591a6b53552,
title = "Alemtuzumab (Campath-1H) in kidney transplantation",
abstract = "Kidney transplantation has become the treatment of choice for both the quality of life and survival in patients with end-stage renal disease (ESRD). However, the immunosuppressive regimen which allows optimal kidney transplant outcome remains elusive. One of the more promising induction agents, Alemtuzumab, was introduced to kidney transplantation by Calne in the late 1990s with low dose cyclosporine A monotherapy, with the hope of establishing 'prope' or near tolerance. Subsequent pilot studies with Alemtuzumab alone or monotherapy (DSG, Rapa) demonstrated high rates of acute rejection (AR) along with occasional humoral components that lead to abandoning the concept of Alemtuzumab as a 'magic bullet' to achieve tolerance, prope or otherwise. A number of programs (including our own) has since modified maintenance immunosuppression using low dose tacrolimus, and shown acceptable rates of AR, with relatively low incidence of viral infection and lymphoproliferative disorders along with cost benefit. However, there are only three prospective, randomized studies which are small with one year or less follow-up, and most published series utilize historical control groups with relatively short follow-up. As extrapolation from short-term data is far from secure, long-term, prospective, randomized studies with Alemtuzumab will be necessary to determine the optimal immunosuppressive regimen.",
keywords = "Acute rejection, Alemtuzumab, Induction therapy, Mycophenolate mofetil, Renal allograft, Sirolimus, Tacrolimus",
author = "Gaetano Ciancio and Burke, {George W}",
year = "2008",
month = "1",
day = "1",
doi = "10.1111/j.1600-6143.2007.02053.x",
language = "English",
volume = "8",
pages = "15--20",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Alemtuzumab (Campath-1H) in kidney transplantation

AU - Ciancio, Gaetano

AU - Burke, George W

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Kidney transplantation has become the treatment of choice for both the quality of life and survival in patients with end-stage renal disease (ESRD). However, the immunosuppressive regimen which allows optimal kidney transplant outcome remains elusive. One of the more promising induction agents, Alemtuzumab, was introduced to kidney transplantation by Calne in the late 1990s with low dose cyclosporine A monotherapy, with the hope of establishing 'prope' or near tolerance. Subsequent pilot studies with Alemtuzumab alone or monotherapy (DSG, Rapa) demonstrated high rates of acute rejection (AR) along with occasional humoral components that lead to abandoning the concept of Alemtuzumab as a 'magic bullet' to achieve tolerance, prope or otherwise. A number of programs (including our own) has since modified maintenance immunosuppression using low dose tacrolimus, and shown acceptable rates of AR, with relatively low incidence of viral infection and lymphoproliferative disorders along with cost benefit. However, there are only three prospective, randomized studies which are small with one year or less follow-up, and most published series utilize historical control groups with relatively short follow-up. As extrapolation from short-term data is far from secure, long-term, prospective, randomized studies with Alemtuzumab will be necessary to determine the optimal immunosuppressive regimen.

AB - Kidney transplantation has become the treatment of choice for both the quality of life and survival in patients with end-stage renal disease (ESRD). However, the immunosuppressive regimen which allows optimal kidney transplant outcome remains elusive. One of the more promising induction agents, Alemtuzumab, was introduced to kidney transplantation by Calne in the late 1990s with low dose cyclosporine A monotherapy, with the hope of establishing 'prope' or near tolerance. Subsequent pilot studies with Alemtuzumab alone or monotherapy (DSG, Rapa) demonstrated high rates of acute rejection (AR) along with occasional humoral components that lead to abandoning the concept of Alemtuzumab as a 'magic bullet' to achieve tolerance, prope or otherwise. A number of programs (including our own) has since modified maintenance immunosuppression using low dose tacrolimus, and shown acceptable rates of AR, with relatively low incidence of viral infection and lymphoproliferative disorders along with cost benefit. However, there are only three prospective, randomized studies which are small with one year or less follow-up, and most published series utilize historical control groups with relatively short follow-up. As extrapolation from short-term data is far from secure, long-term, prospective, randomized studies with Alemtuzumab will be necessary to determine the optimal immunosuppressive regimen.

KW - Acute rejection

KW - Alemtuzumab

KW - Induction therapy

KW - Mycophenolate mofetil

KW - Renal allograft

KW - Sirolimus

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=37549043953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549043953&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2007.02053.x

DO - 10.1111/j.1600-6143.2007.02053.x

M3 - Article

C2 - 18093269

AN - SCOPUS:37549043953

VL - 8

SP - 15

EP - 20

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 1

ER -